Member Info for inanaco

Transfection is the process of deliberately introducing naked or purified nucleic acids into eukaryotic cells.

An ImmunoBody® is a DNA plasmid that encodes a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. ... (a) Direct presentation: ImmunoBody® DNA targets antigen-presenting cells (APCs) directly via transfection.

it encodes ...
BIOCHEMISTRY
(of a gene) be responsible for producing (a substance or behaviour).

Ray what you need is "plasmid dna delivery" in your searches

Bunsie .. spel chek ..wat is it ?

we are talking about the "data in patients " extracted from the Mark 1 ichor unit ... remaining compatible with the mark 2 ..
so can be considered in any deal ...

so from that link you can see everything as a mathematical optimal calculation

so Trigrid equation 1 ... worked

why would you change that ... ?

you cannot improve on "cross presentation" to the Dendritic cell ... scancell has the optimal delivery ... nanovesicle allows a higher dose ... with a similar "quality" delivery because it has no operating electric field which restricts the amount of cells that can be "opened"

they are as i have explained on the other BB .. the syringe is compatible to both, and that cartridge contains the tri grid arrangement in the mark 1 and 2 "the pulse" is so precise that no variation in that is permissible ... so the setup is critical which is why the commercial product i believe removes operator error ... rather than changes the "parameters" this is IMHO
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814886/

point being we have the license off ichor .. deal is done .. so really for Ichor to profit from that ... they need to sort out the FDA
i am not worried about Ichor because we have the mark 2 SCIB1 ... which could start a fresh trial using nanovesicle and double the patient population we could reach ..

because the world cup was so interesting got a taste for it ... and the complexity of a test is far more intriguing that a one day game, never really followed cricket, now i have the twists and turns are fascinating because it really is a "test" and to face a 95 mph 5 oz weight which you can really only see in slow motion just how much it seams and wobbles is impressive

so the past ...

well that is ichor and the FDA ... getting there act together ...

once that's sorted ..

Its price sensitive .. opens up the US trial centers with a fresh IND

this is my problem ...
the past .... that is in the Shareprice ... its the Future that is going to move it ..
Trial is starting ....

so why do i want to understand the past mistakes of the regulatory system or an explanation why .. will it help the future ? .. no
what it highlights is ... Ichor has lead us up the garden path .. promising the TRIGrid 2 .. Scancell has clearly understood that, which isone of the reasons why they moved to Nano vesicle ..
but they could not do that with SCIB1 .. it would invalidate the existing data , and clearly time spent with the FDA has created a Boris Moment ... we are leaving .. !! can't negotiate with you guys

but scancell is not going to talk down Ichor in public . that would not happen because of existing NDA etc

do i want to listen to 20 mins of questions about Funding ...

Cricket ....

i know .... but an RNS is not about "public relations" ... its about giving the market information that could effect the SP ..

so the "out of date " scib1 ... RNS ... was not a Public relation exercise ..

see my point ?

and i was just pointing out that ""reach RNS"" exists which is not an RNS ... because the market has been informed its a Go
ie No Regulatory impediment which is the only thing that has the ability to be price sensitive in this situation ..

its on the pdf link i posted earlier .... this potential share issue resolution is standard practice ... considering we are still in a development phase, if it was not there .. that would raise eyebrows and give an indication that something is coming

if you read the resolutions proposed C7 nothing jumps out of the page, so IMHO nothing in the AGM apart from standard process stuff ... but that is not to say an RNS disclosure before the AGM could change the dynamics or Lindy does one of her "this is what we have discovered" presentations based on RNS already delivered ... ie Homocitruline etc and She is advancing on that ...

resolutions are already listed ...

C7 it could be a " RNS reach " that is why

Not sure actually it needs an RNS now they have already informed the market its a Go on all fronts